Skip to main content
Equibles
BMY logo

BMY · Bristol Myers Squibb Co

Track BMY — free

Use BMY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BMY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$63.43 +1.11 (+1.78%) At close · Nov 13
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$129.66B
Shares
2.04B
Volume · Nov 13 9.27M Avg daily vol (3M) 10.87M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$63.43 Open$62.56 Day$61.81–63.79 52W close$45.79–68.09 Avg vol 30d11.5M Short int46.8M · 2.3% of shares · 4.2d Short vol53% Last earningsOct 29, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 29

Up next

Next earnings call
Feb 4, 2027 Est · unconfirmed · in 12 wks
Q3 2026 earnings call transcript
call held Oct 29, 2026
Play latest call

Latest documents

2026
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

BMS reported third-quarter 2026 revenue of $13,069 million, up 7%, and GAAP EPS of $1.05 versus $1.08; nine-month revenue was $37,532 million, up 5%, with GAAP EPS of $3.98 versus $2.93.

Revenue $13.07B ▲ 6.9% Net income $2.16B ▼ 1.8% Diluted EPS $1.05 ▼ 2.8%
Read from the MD&A section
Oct 29
Earnings call
Q3 2026 earnings call

Bristol-Myers Squibb reported third-quarter revenue of approximately $13.1 billion, up 7%, raised 2026 non-GAAP EPS guidance to $6.35 to $6.55, and posted growth portfolio revenue of $7.7 billion, up 12%.

Oct 29
Current report 8-K
Revenue rose 7%; full-year outlook raised

Third-quarter revenue increased 7% to $13.1 billion and Growth Portfolio revenue increased 12% to $7.7 billion. Bristol Myers Squibb raised 2026 revenue guidance to $49.75 billion to $50.25 billion and updated non-GAAP EPS to $6.35 to $6.55.

Financial results, Regulation FD disclosure Read from the first part of this long document
4 source passages
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 and Raises Full-Year Revenue Outlook Third quarter revenues increased 7% to $13.1 billion Growth Portfolio revenues increased 12% to $7.7 billion Raising 2026 revenue guidance to a range of $49.75 billion to $50.25 billion; Updating non-GAAP EPS range to $6.35 to $6.55, inclusive of a $(0.60) per share net impact from Acquired IPRD charges and licensing income Open the document at this passage
Jul 30
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $12.97B ▲ 5.7% Net income $3.32B ▲ 153.2% Diluted EPS $1.62 ▲ 153.1%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$50.03B
Trailing 12 months
Net income (TTM)
$9.24B
Trailing 12 months
Revenue growth YoY
+6.9%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
14.0
Trailing earnings · reciprocal yield 7.1%
FCF yield
7.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$33.30B
Latest balance sheet
Dividend yield
4.0%
Trailing 12 months
Shares change YoY
+0.7%
Year over year · more shares
Price change (1Y)
+30.4%
Trailing year
Short interest
2.3%
Latest settlement · 4.2 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲7.5% $12.34B $72.00M '24 Q4* ▼5.6% $11.20B $2.46B '25 Q1 ▲0.6% $12.27B $1.31B '25 Q2 ▲2.8% $12.22B $2.20B '25 Q3 ▲1.3% $12.50B $1.09B '25 Q4* ▲2.6% $11.49B $2.68B '26 Q1 ▲5.7% $12.97B $3.32B '26 Q2 LATEST ▲6.9% $13.07B $2.16B '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q3 FY26 earnings call · Oct 29, 2026
Q3 FY26

TL;DR. BMS raised full-year revenue guidance as Growth Portfolio revenue grew 12%, supported by strong product performance, positive registrational data, new approvals, and U.S. manufacturing investments. The outlook remains constrained by gross-margin compression, lower EPS guidance, declining Opdivo and legacy revenue, Eliquis’ expected 2027 step-down, and the paused zola-cel autoimmune program after a fatal safety event.

Bullish
  • + Full-year revenue guidance was raised to approximately $49.75 billion–$50.25 billion from approximately $49.0 billion–$50.0 billion. new
  • + Q3 Growth Portfolio revenue increased 12% to $7.7 billion. new
  • + BMS generated approximately $4.2 billion of operating cash flow and held approximately $13.0 billion of total cash. new
  • + The company reported multiple positive registrational readouts and regulatory approvals across therapeutic areas. new
  • + BMS announced approximately $2.3 billion for a Houston manufacturing campus and more than $173 million for a new Indiana radiopharmaceutical facility. new
Bearish
  • − Non-GAAP gross margin declined 450 bps to 68.4% from 72.9%. new
  • − Full-year legacy-portfolio revenue is now expected to decline 3%–5%. new
  • − BMS anticipates a $1.5 billion–$2 billion Eliquis revenue step-down in 2027. new
  • − Full-year non-GAAP EPS guidance was lowered to $6.35–$6.55 from $6.75–$7.00, including a $(0.60) impact from acquired IPRD and licensing income. new
  • − The zola-cel autoimmune clinical program is paused after one patient died from septic pneumonia. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +5%
above
Price vs 50-day avg +2%
above
RSI (14) 56
neutral
MACD trend Positive
52-week position 79%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +6%
trailing
6-month return +9%
trailing
YTD return +18%
this year
Relative strength +9%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $62 › 200d $60 — 50d above 200d
Institutional flow Accumulating
2,365 of 2,558 funds reported for Sep 30 · net +11.9M sh shares · +161 new
Insider flow Distributing
Net -$677.8K over 90 days · 100% sells
Short interest Falling
2.29% of shares out · ▼ -6.2% MoM · 4.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
2,558 holders — near 3-yr high, broad support
Squeeze score 57
elevated · 0–100
Fundamentals
Strong
Revenue growth −0%
Y/Y
Gross margin 64%
expanding
EPS growth +178%
Y/Y
Free cash flow $12.8B
Valuation P/E 14
below peers
Buyback $5.0B
remaining
Balance sheet $34.9B
net debt
Quant / Vol
risk profile
Moderate
Volatility 28%
annualized · 1-yr
Max drawdown −17%
past year
ATR 2.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 3
Latest guidance · from the 8-K filed Oct 29, 2026
2026
Total Revenues (Reported & Ex-FX) Non-GAAP Raised $49.75B – $50.25B
Jul 30, 2026 $49B – $50B changed to Oct 29, 2026 $49.75B – $50.25B
Diluted EPS Non-GAAP Lowered $6.35 – $6.55
Jul 30, 2026 $6.75 – $7.00 changed to Oct 29, 2026 $6.35 – $6.55
2026 Guidance
Gross Margin % Non-GAAP Maintained 69% – 70%
Apr 30, 2026 69% – 70% changed to Oct 29, 2026 69% – 70%
Operating Expenses Non-GAAP Maintained $16.5B
Jul 30, 2026 $16.5B changed to Oct 29, 2026 $16.5B
Tax Rate Non-GAAP Maintained 18%
Apr 30, 2026 18% changed to Oct 29, 2026 18%
Acquired IPRD Charge & Licensing Income Included in Diluted EPS Non-GAAP $-0.60
Previous outlook earlier release · from the 8-K filed Apr 30, 2026

Still-open targets the latest release did not restate under the same label.

Effective tax rate · 2026 18%
WW Eliquis Revenue Growth · 2026 10% – 15%
Guided vs delivered · last 3 settled
GAAP diluted EPS 2023
guided $3.68 – $3.83
$3.86 Beat +2.8%
Total net sales 2022
guided $46B
$46.16B Beat +0.3%
Diluted EPS 2022 Guidance
guided $2.92 – $3.22
$2.95 In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+5% Bullish
Price vs 50-day avg
+2% Bullish
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
79% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $62 › 200d $60 — 50d above 200d
Institutional flow Accumulating
2,365 of 2,558 funds reported for Sep 30 · net +11.9M sh shares · +161 new
Insider flow Distributing
Net -$677.8K over 90 days · 100% sells
Short interest Falling
2.29% of shares out · ▼ -6.2% MoM · 4.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
2,558 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $46 Now $63 · 79% Range high $68
vs 200-day avg +5% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash flow from Operations $3.4B Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BMY
Bristol Myers Squibb Co
this stock
$129.66B +17.6% -0.2% 14.0 2.3%
LLY
ELI LILLY & Co
 $1.36T +34.3% +44.7% 46.9 0.8%
JNJ
Johnson & Johnson
 $687.89B +38.1% +6.0% 43.4 0.7%
ABBV
AbbVie Inc.
 $521.50B +29.1% +8.6% 50.8 0.9%
MRK
Merck & Co., Inc.
 $364.26B +40.4% +1.3% 152.3 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
2,632
% held
84.8%
Reported
2,365 of 2,558
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,293
View
Short & Settlement
Short Interest Falling
Shares short
46.8M
Days to cover
4.2d
Change
-3.1M sh
View
Short Volume
Short vol %
53%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
909
Value
$51.5K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
38.4%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$677.8K
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Sell
Member
Mike Kelly
Amount
$15.0K–$50.0K
Traded
May 7, 2026
View
Financials
Financials
Revenue (FY)
$48.2B
Net income (FY)
$7.1B
EPS diluted
$3.46
View
Buybacks
Remaining
$5.0B
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 29, 2026
This year
17

BMS reported third-quarter 2026 revenue of $13,069 million, up 7%, and GAAP EPS of $1.05 versus $1.08; nine-month revenue was $37,532 million, up 5%, with GAAP EPS of $3.98 versus $2.93.

View
Proposed Sales
Value
$403.5K
Shares
6.2K
Filed
Sep 9, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 29, 2026
View
Investor Relations
Latest news
Bristol Myers Squibb Announces Ev…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
BMY +2.1% +6.2% +9.3% +1.5% +17.6%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -0.5% +7.3% +8.8% +1.7% +7.0%

Capital returns

Latest dividend
$0.63 / share · ex Oct 2, 2026
Raised 1.6%
Paid (TTM)
$2.52 / share · 4 payouts
Dividend yield (TTM, derived)
3.97%
Full dividend history
Buyback program · as of Dec 31, 2025
Authorized
—
Spent (derived)
—
Remaining
$5.00B

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 14272 CUSIP 110122108 13F (30d) 2056 filings 1929 filers Visit website Investor relations